Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CDTX

Cidara Therapeutics Inc

Dec 10 • 04:00PM ET

22.17

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: JNJ GILD REGN PFE AMGN MRNA VRTX BMY SNY BIIB

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-25.55	Insider Own	37.06%	Shs Outstand	7.05M	Perf Week	25.18%
Market Cap	156.22M	Forward P/E	-	EPS next Y	-10.31	Insider Trans	0.24%	Shs Float	4.44M	Perf Month	64.22%
Income	-121.33M	PEG	-	EPS next Q	-3.86	Inst Own	43.09%	Short Float	1.19%	Perf Quarter	90.79%
Sales	26.35M	P/S	5.93	EPS this Y	-369.85%	Inst Trans	-	Short Ratio	1.39	Perf Half Y	63.62%
Book/sh	16.41	P/B	1.35	EPS next Y	57.81%	ROA	-111.32%	Short Interest	0.05M	Perf Year	49.82%
Cash/sh	18.08	P/C	1.23	EPS next 5Y	-	ROE	-203.26%	52W Range	10.00 - 24.40	Perf YTD	39.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	37.54%	ROI	-102.83%	52W High	-9.14%	Beta	1.06
Dividend TTM	-	Quick Ratio	3.54	Sales past 5Y	59.53%	Gross Margin	89.31%	52W Low	121.61%	ATR (14)	1.88
Dividend Ex-Date	-	Current Ratio	3.54	EPS Y/Y TTM	-234.93%	Oper. Margin	-171.78%	RSI (14)	67.52	Volatility	15.13% 10.68%
Employees	69	Debt/Eq	0.03	Sales Y/Y TTM	-53.40%	Profit Margin	-460.50%	Recom	1.00	Target Price	31.75
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	-35.23%	Payout	-	Rel Volume	0.00	Prev Close	22.17
Sales Surprise	-100.00%	EPS Surprise	42.35%	Sales Q/Q	-100.00%	Earnings	Nov 07 AMC	Avg Volume	37.89K	Price	22.17
SMA20	22.08%	SMA50	54.96%	SMA200	65.47%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Guggenheim	Buy	$33
Aug-14-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24
Dec-03-21	Resumed	H.C. Wainwright	Buy	$6
Sep-22-21	Upgrade	WBB Securities	Buy → Strong Buy	$6.25
Mar-04-21	Initiated	Aegis Capital	Buy	$9
Sep-04-19	Upgrade	Wedbush	Neutral → Outperform	$2 → $4
Jul-26-18	Initiated	Citigroup	Buy	$8
Apr-21-17	Initiated	Raymond James	Strong Buy
Apr-17-17	Reiterated	H.C. Wainwright	Buy	$18 → $14
Apr-12-17	Initiated	Ladenburg Thalmann	Buy	$11.25
Apr-11-17	Resumed	Wedbush	Outperform	$13
Feb-22-17	Upgrade	WBB Securities	Sell → Hold	$7.25
Feb-22-17	Reiterated	H.C. Wainwright	Buy	$25 → $18
Dec-21-16	Resumed	Leerink Partners	Outperform
Dec-19-16	Initiated	H.C. Wainwright	Buy	$25
Sep-23-16	Downgrade	WBB Securities	Hold → Sell	$10.50
Oct-09-15	Upgrade	WBB Securities	Sell → Hold	$13
May-11-15	Initiated	Wedbush	Outperform	$22
May-11-15	Initiated	Needham	Buy	$20
May-11-15	Initiated	Leerink Partners	Outperform	$24

Show Previous Ratings

Dec-05-24 11:07AM	Cidara achieves full enrolment in influenza prevention trial (Clinical Trials Arena)
Dec-04-24 08:00AM	Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza (GlobeNewswire) +12.65%
Dec-03-24 09:55AM	Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) -5.60%
Nov-21-24 08:30AM	Cidara Therapeutics Announces $105 Million Private Placement (GlobeNewswire) +15.41%
Nov-19-24 08:00AM	Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference (GlobeNewswire)
05:09PM	Loading…
Nov-07-24 05:09PM	Cidara Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 08:00AM	Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences (GlobeNewswire)
Oct-16-24 08:00AM	Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 (GlobeNewswire) +5.60%
Oct-04-24 04:30PM	Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-25-24 08:00AM	Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference (GlobeNewswire)
Sep-23-24 08:00AM	Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza (GlobeNewswire)
Sep-19-24 08:00AM	Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts (GlobeNewswire)
Sep-13-24 10:13AM	Cidara axes 30% of staff to focus on flu prevention drug (Pharmaceutical Technology) +5.20%
07:53AM	Cidara buys back rights to flu therapy from J&J for $85m (Pharmaceutical Technology)
04:05PM	Loading…
Sep-12-24 04:05PM	Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 (GlobeNewswire)
Sep-05-24 08:00AM	Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-19-24 05:12PM	Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer (GlobeNewswire)
Aug-13-24 05:25PM	Cidara Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +5.84%
04:29PM	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-03-24 01:05PM	Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-24 08:00AM	Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference (GlobeNewswire) +5.08%
May-15-24 10:54PM	CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.59%
04:30PM	Cidara Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:20PM	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
04:01PM	Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules (GlobeNewswire)
Apr-26-24 08:00AM	Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 (GlobeNewswire)
Apr-25-24 07:52AM	Top Premarket Gainers (MT Newswires) +5.78%
Apr-24-24 04:05PM	Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million (GlobeNewswire) +19.90%
04:01PM	Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline (GlobeNewswire)
05:11AM	Loading…
Apr-23-24 05:11AM	Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket (MT Newswires)
Apr-22-24 09:52PM	CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -24.54%
05:10PM	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
05:06PM	Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice (GlobeNewswire)
08:49AM	Cidara Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-05-24 03:00PM	Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +7.41%
Mar-06-24 08:00AM	Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
08:00AM	Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Feb-15-24 03:15AM	Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio (GuruFocus.com)
Feb-12-24 08:00AM	Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO (GlobeNewswire)
Jan-29-24 04:30PM	Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults (GlobeNewswire)
Dec-26-23 10:51AM	Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis (Zacks) -5.49%
Dec-22-23 07:30AM	Cidara Therapeutics Announces European Approval of REZZAYO (rezafungin) for the Treatment of Invasive Candidiasis in Adults (GlobeNewswire) +11.13%
Dec-07-23 08:00AM	Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire)
Dec-06-23 08:00AM	Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China (GlobeNewswire)
Nov-30-23 08:00AM	Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire)
Nov-20-23 08:00AM	Cidara Therapeutics Named as a San Diego Metro Area Top Workplace (GlobeNewswire)
Nov-03-23 12:00PM	Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC's 38 Annual Meeting (GlobeNewswire) -6.33%
Nov-02-23 07:33PM	Cidara Therapeutics Inc (CDTX) Reports Q3 2023 Financial Results (GuruFocus.com) +7.62%
04:32PM	Cidara Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-13-23 10:34AM	Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1) (GlobeNewswire)
Oct-11-23 08:30AM	Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023 (GlobeNewswire)
Sep-29-23 04:51PM	Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-23 08:00AM	Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023 (GlobeNewswire)
Sep-14-23 01:17AM	Insider Sell: Chief Scientific Officer Leslie Tari Sells 18,469 Shares of Cidara Therapeutics Inc (GuruFocus.com)
Sep-07-23 08:00AM	Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire) +26.07%
08:00AM	Cidara Therapeutics Announces Janssens Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza (GlobeNewswire)
Aug-28-23 10:17PM	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now (InvestorPlace) +7.01%
Aug-16-23 08:00AM	Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development (GlobeNewswire)
Aug-09-23 06:04AM	Downgrade: Here's How Analysts See Cidara Therapeutics, Inc. (NASDAQ:CDTX) Performing In The Near Term (Simply Wall St.)
Aug-06-23 08:24AM	Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) Shift From Loss To Profit (Simply Wall St.)
Aug-03-23 05:25PM	Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Cidara Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:08PM	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 04:30PM	Cidara Therapeutics Provides Update on REZZAYO (rezafungin for injection) (GlobeNewswire)
Jul-20-23 05:00PM	Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program (GlobeNewswire)
Jul-14-23 09:38AM	Retail investors account for 58% of Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) ownership, while institutions account for 20% (Simply Wall St.)
Jun-26-23 08:00AM	Cidara Therapeutics Added to Russell Microcap® Index (GlobeNewswire)
Jun-22-23 08:00AM	Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B (GlobeNewswire) +6.36%
Jun-20-23 09:55AM	Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit (GlobeNewswire)
Jun-13-23 08:00AM	Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit (GlobeNewswire)
07:24AM	Cidara Therapeutics' (NASDAQ:CDTX) investors will be pleased with their impressive 146% return over the last year (Simply Wall St.)
May-14-23 09:06AM	We're Not Very Worried About Cidara Therapeutics' (NASDAQ:CDTX) Cash Burn Rate (Simply Wall St.)
May-11-23 04:51PM	Cidara Therapeutics: Q1 Earnings Snapshot (AP Finance) +6.31%
04:37PM	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 04:30PM	Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference (GlobeNewswire)
Apr-24-23 08:00AM	Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO (GlobeNewswire) -5.31%
Apr-17-23 06:45AM	Cidara Therapeutics, Inc. (NASDAQ:CDTX) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough (Simply Wall St.) +5.56%
Apr-04-23 12:44PM	Are Options Traders Betting on a Big Move in Cidara (CDTX) Stock? (Zacks)
Mar-31-23 08:00AM	Cidara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-23 09:13AM	Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Slashed This Year's Estimates (Simply Wall St.)
Mar-23-23 12:35PM	Cidara's Lower Than Expected Q4 Earnings Overshadows FDA Nod For Antifungal Treatment (Benzinga) -24.74%
10:19AM	5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science (GlobeNewswire)
08:35AM	Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-22-23 05:26PM	Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis (Business Wire)
Mar-07-23 04:15PM	Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress (GlobeNewswire) +6.45%
04:01PM	Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock (GlobeNewswire)
Mar-03-23 09:14AM	Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock (GlobeNewswire) -14.09%
Mar-02-23 04:14PM	Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock (GlobeNewswire) -7.65%
Mar-01-23 12:54PM	Johnson & Johnson-Backed Antiviral Candidate Effectively Prevents Influenza Infection (Benzinga) +29.80%
07:00AM	Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model (GlobeNewswire)
Feb-28-23 08:00AM	Cidara to Present at ESMO Targeted Anticancer Therapies Congress (GlobeNewswire)
Feb-14-23 08:00AM	Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-04-23 07:42AM	Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) market cap surged US$21m last week, individual investors who have a lot riding on the company were rewarded (Simply Wall St.)
Feb-01-23 08:00AM	Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidaras CD73 Oncology DFC Program (GlobeNewswire)
Jan-25-23 11:02AM	Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis (Business Wire) +37.92%
Jan-04-23 08:00AM	Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform (GlobeNewswire) +8.53%

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sandison Taylor	Chief Medical Officer	Sep 11 '24	Sale	11.64	924	10,752	23,067	Sep 13 06:27 PM
Tari Leslie	CHIEF SCIENTIFIC OFFICER	Sep 11 '24	Sale	11.64	909	10,580	17,788	Sep 13 06:26 PM
Stein Jeffrey	President & CEO	Jun 07 '24	Buy	13.21	8,000	105,680	24,580	Jun 11 06:26 PM
Tari Leslie	CHIEF SCIENTIFIC OFFICER	Mar 11 '24	Sale	0.67	21,029	14,085	258,681	Mar 12 09:48 PM
Sandison Taylor	Chief Medical Officer	Mar 11 '24	Sale	0.67	20,662	13,839	347,095	Mar 12 09:47 PM
Ward Shane	COO & CLO	Mar 11 '24	Sale	0.67	20,473	13,713	198,770	Mar 12 09:46 PM
Shah Preetam	CFO & CBO	Mar 11 '24	Sale	0.67	18,931	12,680	227,210	Mar 12 09:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CDTX

Cidara Therapeutics Inc

Upgrade your FINVIZ experience